Objective: To identify predictive variables of iron overload in patients with sickle cell anemia, correlating biochemical and imaging markers. Materials and Methods: The authors developed a cross-sectional study involving 32 patients with sickle cell anemia who were evaluated for ferritin and iron serum levels and submitted to liver magnetic resonance imaging with one spin-echo and five gradient-echo sequences. The signal intensity was obtained at each sequence, corresponding to the arithmetical mean of the measurements on regions of interest in the liver and paraspinal muscles to obtain the liver/muscle signal intensity ratio (SIR). Based on such SIR, the liver iron concentration (LIC) was estimated by means of the following formula: e^{[5.808 – (0.877 × T2*) – (1.518 × IW)]}, where T2* is the SIR on the sequence with echo time = 13 ms and IW is the SIR on the intermediate-weighted sequence. Patients were grouped according to their blood transfusion regimen (regular monthly versus sporadic transfusions). Results: The comparison between the transfusion groups was based on clinical-laboratory variables, with significant differences in SIR, LIC and serum ferritin levels: the group with regular transfusions demonstrated greater hepatic iron overload. Conclusion: Magnetic resonance imaging is an efficient tool for evaluating liver iron overload in patients with sickle cell anemia.

Keywords: Sickle cell anemia; Magnetic resonance imaging; Ferritin.

OBJECTIVE: To evaluate sonographic features associated with morbidity in patients with chronic clinical presentations of schistosomiasis mansoni, according to the protocol proposed by the World Health Organization (WHO). Materials and Methods: Two distinctive populations were evaluated: a) patients from an endemic area, and b) patients from a tertiary institution, with histopathologically confirmed periportal fibrosis. INCLUSION CRITERIA: diagnosis confirmed by parasitological stool examination for Schistosoma mansoni (Kato-Katz method). EXCLUSION CRITERIA: positive serology for HIV, HTLV-1, HBV or HCV. The Niamey protocol on ultrasonography proposed by the WHO was utilized. RESULTS:As the measures of periportal spaces were isolatedly evaluated, no alteration was observed in 21% of the tertiary institution patients with advanced disease. As all parameters of the Niamey protocol were considered, 100% of patients from the tertiary institution, with severe disease, presented advanced periportal fibrosis. In hepatosplenic patients from endemic areas, fibrosis was not identified at ultrasonography. CONCLUSION: The sonographic protocol proposed by the WHO can detect advanced periportal fibrosis in patients with severe form of disease with higher sensitivity than the isolated measurement of periportal space. The complexity involved in the sonographic identification of early stages of periportal fibrosis in endemic areas may give rise to the field of diagnostic supplementation and to a continued improvement of sonographic protocols in these areas.

Keywords: Schistosomiasis mansoni; Morbidity; Periportal fibrosis; Ultrasonography.